The FDA has approved Extavia (interferon beta-1b injection, from Novartis) for the treatment of relapsing forms of multiple sclerosis (MS) to reduce the frequency of clinical exacerbations. Extavia is also indicated for patients who have experienced a first clinical episode of MS and have features consistent with the disease as shown by magnetic resonance imaging (MRI).
The same medicinal product as Betaseron (from Bayer Schering), Extavia offers patients and physicians a new branded version of interferon beta-1b. Extavia is expected be available in the fall of 2009.
For more information call (800) 693-9993 or visit www.novartis.com.